The National Healthcare Security Administration (NHSA) and National Health Commission (NHC) of China have released the “Notice on Improving the Working Mechanism for Volume-based Procurement (VBP) and its Implementation.” The notice outlines refined measures for hospital access, use, monitoring, examination, and feedback in relation to VBP drugs and consumables.<\/p>\n\n\n\n
Urging Winning Bid Products into Hospitals<\/strong> Strengthening Usage Management<\/strong> Implementing the Surplus Retention Policy<\/strong>
Local authorities are mandated to conduct investigations and sorting from the third month of each VBP batch’s implementation, urging medical institutions to complete access work as soon as possible. For institutions with policies restricting generic drugs to two specifications per molecule, it is encouraged to prioritize drugs by winning backup manufacturers when selecting drugs with the same generic name. Village clinics, private medical institutions, and retail pharmacies are also encouraged to participate in VBP, ensuring convenience for the public in purchasing winning bids.<\/p>\n\n\n\n
Medical institutions are required to improve internal assessment methods and salary systems, strengthen prescription reviews, and give reasonable priority to the use of winning bids. National medical centers and industry associations are encouraged to develop medication guidelines and conduct real-world research on winning bid drugs and consumables, providing scientific guidance for rational and prioritized use.<\/p>\n\n\n\n
Regions are to provide surplus retention incentives to medical institutions for the medical insurance funds saved by national and provincial VBP rounds, in accordance with relevant regulations. Localities must connect the surplus retention policy with the incentive and restraint mechanism for payment method reform, reflecting positive incentives for medical institutions to purchase and use winning bid drugs and consumables.<\/p>\n\n\n\n